| Remimazolam – current knowledge on a new intravenous benzodiazepine anesthetic agent |
Seong-Hyop Kim1,2 
, Jörg Fechner3
|
1Department of Anesthesiology and Pain medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea
2Department of Medicine, Institute of Biomedical Science and Technology, Konkuk University School of Medicine, Seoul, Korea
3Department of Anesthesiology, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany |
Corresponding author:
Jörg Fechner, Tel: +49-913-1854-2731, Fax: +49-913-1853-6147,
Email: drfechner@mac.com
|
|
Received: 17 March 2022 • Revised: 15 May 2022 • Accepted: 16 May 2022 |
|
|
| Abstract |
|
Intravenous anesthetic agents such as midazolam, propofol, and ketamine are routinely used to provide anesthesia and sedation. They have been shown to effectively induce and maintain amnesia, sedation, and hypnosis in various patient groups and clinical settings. However, all anesthetic agents have the potential to cause unwanted side effects such as hemodynamic instability, respiratory depression, or slow recovery due to prolonged post-procedural sedation. Remimazolam, a recently approved benzodiazepine for general anesthesia and procedural sedation in Korea, has been successfully used for these purposes. To date, inconclusive knowledge has been obtained regarding the use of remimazolam in different patient populations and under various surgical conditions. With respect to the specific pharmacokinetic and pharmacodynamic characteristics of remimazolam, the use of remimazolam is expected to increase providing safe general anesthesia and sedation. This review aims to provide an overview of the basic and clinical pharmacology of remimazolam and to compare it with midazolam and propofol. |
| Key Words:
Amnesia; Anesthesia; Benzodiazepine; Conscious sedation; Hypnosis; Remimazolam. |
|
PDF Links
XML Download
Full text via DOI
Download Citation
CrossRef TDM
E-Mail
Print
